Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
← catalyst calendarNCT04260022 · readout in 1,226 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
242estimated
Sites
9
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-01-09 | actual | When the study began enrolling |
| Primary completion | 2029-12-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Leukemia, Myeloid, Chronic
- Myeloid Leukemia
- Chronic Myeloid Leukemia
- Philadelphia Positive Acute Lymphoblastic Leukemia
- B Cell Precursor Type Acute Leukemia
Interventions
- Drug: Ascentage Pharma HQP1351 bioavailable inhibitor
- Drug: Blinatumomab — also filed as Blincyto
Primary outcomes
what the primary-completion date above is the date OFMaximum Plasma Concentration (Cmax) of HQP1351
measured 28 days
Area Under the Curve (AUC) of HQP1351
measured 28 days
Publications
- PMID 39570620 — linked by the registry
- PMID 35982483 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed